Vasilios Karageorgiou

Dr. Vasilios Karageorgiou

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Schizophrenia Research
Verified
Journal Article
Closed access
VKVasilios Karageorgiou
Vasilios Karageorgiou
GMGerasimos P. Milas
Gerasimos P. Milas
IMIoannis Michopoulos
Ioannis Michopoulos

13 March 2019 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
MKMaria Katsigianni
Maria Katsigianni
VKVasilios Karageorgiou
Vasilios Karageorgiou
ILIrene Lambrinoudaki
Irene Lambrinoudaki
CSCharalampos Siristatidis
Charalampos Siristatidis

1 January 2019 in Metabolism
Verified
Journal Article
Closed access
VKVasilios Karageorgiou
Vasilios Karageorgiou
Theodore G. PapaioannouTheodore G. Papaioannou
Theodore G. Papaioannou
IBIoannis Bellos
Ioannis Bellos
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
NTNikolaos Tentolouris
Nikolaos Tentolouris
DTDimitrios Tousoulis
Dimitrios Tousoulis

28 September 2018 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PDF file
IBIoannis Bellos
Ioannis Bellos
VKVasilios Karageorgiou
Vasilios Karageorgiou
DKDimitrios Kapnias
Dimitrios Kapnias
KKKonstantina‐Eleni Karamanli
Konstantina‐Eleni Karamanli
CSCharalampos Siristatidis
Charalampos Siristatidis

14 September 2023 in BMC Medicine
Verified
Journal Article
Open access
PDF file
VKVasilios Karageorgiou
Vasilios Karageorgiou
FCFrancesco Casanova
Francesco Casanova
JOJessica O’lOughlin
Jessica O’lOughlin
HGHarry Green
Harry Green
TMTrevelyan J. McKinley
Trevelyan J. McKinley
JTJessica Tyrrell
Jessica Tyrrell
Background: Major depressive disorder (MDD) has a significant impact on global burden of disease. Complications in clinical management can occur when response to pharmacological modalities is considered inadequate and symptoms persist (treatment-resistant depression (TRD)). We aim to investigate inflammation, proxied by C-reactive protein (CRP) levels, and body mass index (BMI) as putative causal risk factors for depression and subsequent treatment resistance, leveraging genetic information to avoid confounding via Mendelian randomisation (MR).Methods: We used the European UK Biobank subcohort ( $$n=451,025$$n=451,025 ), the mental health questionnaire (MHQ) and clinical records. For treatment resistance, a previously curated phenotype based on general practitioner (GP) records and prescription data was employed.We applied univariable and multivariable MR models to genetically predict the exposures and assess their causal contribution to a range of depression outcomes. We used a range of univariable, multivariable and mediation MR models techniques to address our research question with maximum rigour. In addition, we developed a novel statistical procedure to apply pleiotropy-robust multivariable MR to one sample data and employed a Bayesian bootstrap procedure to accurately quantify estimate uncertainty in mediation analysis which outperforms standard approaches in sparse binary outcomes. Given the flexibility of the one-sample design, we evaluated age and sex as moderators of the effects.Results: In univariable MR models, genetically predicted BMI was positively associated with depression outcomes, including MDD ( $$\beta$$β ( $$95\%$$95% CI): 0.133(0.072, 0.205)) and TRD (0.347(0.002, 0.682)), with a larger magnitude in females and with age acting as a moderator of the effect of BMI on severity of depression (0.22(0.050, 0.389)). Multivariable MR analyses suggested an independent causal effect of BMI on TRD not through CRP (0.395(0.004, 0.732)). Our mediation analyses suggested that the effect of CRP on severity of depression was partly mediated by BMI. Individuals with TRD ( $$n=2199$$n=2199 ) observationally had higher CRP and BMI compared with individuals with MDD alone and healthy controls.Discussion: Our work supports the assertion that BMI exerts a causal effect on a range of clinical and questionnaire-based depression phenotypes, with the effect being stronger in females and in younger individuals. We show that this effect is independent of inflammation proxied by CRP levels as the effects of CRP do not persist when jointly estimated with BMI. This is consistent with previous evidence suggesting that overweight contributed to depression even in the absence of any metabolic consequences. It appears that BMI exerts an effect on TRD that persists when we account for BMI influencing MDD.

1 February 2020 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
VKVasilios Karageorgiou
Vasilios Karageorgiou
TFToshiaki A. Furukawa
Toshiaki A. Furukawa
ETEvdoxia Tsigkaropoulou
Evdoxia Tsigkaropoulou
AKAnna Karavia
Anna Karavia
RGRossetos Gournellis
Rossetos Gournellis
IMIoannis Michopoulos
Ioannis Michopoulos